Protocol Research Designation & Liability
Synergistic protocols aggregated in the MinMaxMuscle archive are for experimental research only. Combining compounds increases physiological complexity and risk. These matrices are NOT medical prescriptions. Full medical consultation is required prior to any research application.
The God Protocol
Peak Human Performance
Archival Status
The God Protocol combines Growth Hormone Secretagogues (CJC-1295 + Ipamorelin), a glucose disposal agent (5-Amino-1MQ), and a mitochondrial repair compound (MOTS-c) into a comprehensive performance enhancement stack targeting four interrelated metabolic systems: GH axis optimization, insulin sensitivity, mitochondrial biogenesis, and body composition. CJC-1295 and Ipamorelin provide synergistic GHRH/GHRP activation of the GH secretory axis, generating increased pulsatile GH release without supraphysiological suppression of endogenous secretion. This amplified GH signaling drives IGF-1 production, lean tissue accretion, lipolysis, and recovery acceleration through IGF-1R and direct GH receptor activation in muscle, bone, and adipose tissue. 5-Amino-1MQ (5-Amino-1-methylquinolinium) is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that downregulates NAD+ biosynthesis in adipose tissue. Inhibiting NNMT increases cellular NAD+ and SAM (S-adenosylmethionine) levels, activating SIRT1 and downstream metabolic programs that promote fat oxidation and insulin sensitivity. Research in diet-induced obesity models shows 5-Amino-1MQ significantly reduces adiposity and improves metabolic markers without apparent toxicity. Its synergy with GH secretagogues is mechanistic: elevated GH enhances lipolysis, while 5-Amino-1MQ improves the metabolic efficiency of liberated fatty acids. MOTS-c adds mitochondrial optimization to the protocol by activating AMPK and nuclear stress response pathways that improve mitochondrial biogenesis and metabolic flexibility — the ability to efficiently switch between glucose and fat as fuel substrates. This is particularly relevant during periods of caloric restriction or high-intensity training when metabolic demands outpace baseline mitochondrial capacity. The integrated rationale is total performance optimization: GH axis stimulation for anabolic signaling, NNMT inhibition for metabolic efficiency, and MOTS-c for mitochondrial infrastructure — each targeting a distinct but complementary aspect of the performance equation. This protocol is studied in research contexts involving body recomposition, athletic performance enhancement, and age-associated metabolic decline.
Synergy Matrix
Active Research Thread
Join the ongoing discussion regarding clinical outcomes and anecdotal observations for this protocol.
Discuss in ForumClinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Protocol Rank | Rank: 0 |
| Optimization Goal | Peak Human Performance |
Clinical Pros
- Synergistic biological signaling
- Optimized pharmacokinetic alignment
- Targeted metabolic pathway focus
Research Limitations
- Requires precise administration timing
- Cumulative cost of protocol components
- Advanced cycle monitoring recommended